Literature DB >> 11602863

Early peri-operative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study.

M C Thomas1, T H Mathew, G R Russ, M M Rao, J Moran.   

Abstract

BACKGROUND: Hyperglycemia alters the inflammatory response to infection and ischemia. We hypothesize that perioperative glycemic control could also influence the risk for allograft rejection.
METHODS: Consecutive patients with established diabetes undergoing their first cadaveric renal transplantation and receiving steroid-sparing immunosuppression were identified (n=50). Records of capillary glucose observations over the first 100 hr following surgery and transplantation variables pertaining to graft function, acute rejection, and postoperative infection were identified and entered into multivariate analysis.
RESULTS: Perioperative glycemic control was associated with an increased incidence of infection and acute rejection. Only 3 of 27 patients (11%) with optimal glycemic control during the 100 hr following surgery (mean<11.2 mmol/L) had rejection episodes compared with 58% of patients with poor control (>11.2 mmol/L). All patients with poor glycemic control experienced postoperative infection.
CONCLUSIONS: This pilot study suggests that hyperglycemia may be associated with an increased risk of both allograft rejection and postoperative infection in patients with diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602863     DOI: 10.1097/00007890-200110150-00024

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  21 in total

1.  Modeling Inpatient Glucose Management Programs on Hospital Infection Control Programs: An Infrastructural Model of Excellence.

Authors:  Nestoras Mathioudakis; Peter J Pronovost; Sara E Cosgrove; Daniel Hager; Sherita Hill Golden
Journal:  Jt Comm J Qual Patient Saf       Date:  2015-07

2.  Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study.

Authors:  Amisha Wallia; Kathleen Schmidt; Diana Johnson Oakes; Teresa Pollack; Nicholas Welsh; Susan Kling-Colson; Suruchi Gupta; Candice Fulkerson; Grazia Aleppo; Neehar Parikh; Josh Levitsky; J P Norvell; Alfred Rademaker; Mark E Molitch
Journal:  J Clin Endocrinol Metab       Date:  2017-02-01       Impact factor: 5.958

Review 3.  Hyperglycemia in critical illness: a review.

Authors:  David Brealey; Mervyn Singer
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

4.  Type 2 diabetes mellitus and risk of cutaneous squamous cell carcinoma.

Authors:  Steven T Chen; Tricia Li; Jiali Han; Abrar A Qureshi; Eunyoung Cho
Journal:  J Am Acad Dermatol       Date:  2016-10       Impact factor: 11.527

Review 5.  Diabetes and kidney transplantation: past, present, and future.

Authors:  Giselle Guerra; Amna Ilahe; Gaetano Ciancio
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

Review 6.  Metabolic Disorders with Kidney Transplant.

Authors:  Elizabeth Cohen; Maria Korah; Glenda Callender; Renata Belfort de Aguiar; Danielle Haakinson
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-13       Impact factor: 8.237

Review 7.  Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes.

Authors:  David Baldwin; Jill Apel
Journal:  Curr Diab Rep       Date:  2013-02       Impact factor: 4.810

Review 8.  Inpatient diabetology. The new frontier.

Authors:  Nicolas N Abourizk; Chaula K Vora; Parveen K Verma
Journal:  J Gen Intern Med       Date:  2004-05       Impact factor: 5.128

9.  Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection.

Authors:  Amisha Wallia; Neehar D Parikh; Mark E Molitch; Eileen Mahler; Lu Tian; Jie Jenny Huang; Josh Levitsky
Journal:  Transplantation       Date:  2010-01-27       Impact factor: 4.939

Review 10.  Hyperglycemia and Diabetes Mellitus Following Organ Transplantation.

Authors:  Rodolfo J Galindo; Amisha Wallia
Journal:  Curr Diab Rep       Date:  2016-02       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.